Novartis Casts It Immuno-Oncology Nets Wider As PD1 Catch Gets Away
This article was originally published in Scrip
Novartis has revealed a series of deals which widen its net in immune-oncology, and hopefully compensate for falling behind some of its competitors in this key development area.
You may also be interested in...
Juno Therapeutics Inc. has followed in the footsteps of some of its big pharma rivals, Novartis and AstraZeneca, by acquiring RedoxTherapies, Inc. for its small molecule adenosine A2a (A2a) receptor antagonist vipadenant.
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.